Skip to main content
Erschienen in:

08.08.2019 | Originalien

Intravenous esomeprazole versus pantoprazole for heartburn

A randomized controlled double-blind trial

verfasst von: O. Karakayali, S. Yilmaz, Prof., A. Karakayali, Yavuz Yigit, Huseyin Cahit Halhalli, Tolga Uslu

Erschienen in: Notfall + Rettungsmedizin | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Heartburn is one of the most common symptoms of gastrointestinal diseases. Intravenous (IV) administration of pantoprazole, lansoprazole, and esomeprazole is recommended by the US Food and Drug Administration (FDA) for short-term acute treatment. Although there are many studies on these drugs in the literature, they are frequently related to long-term oral use and changes in intragastric pH.

Objective

This study compared the effects of IV esomeprazole with those of IV pantoprazole in patients presenting to the emergency department with heartburn.

Materials and methods

For this randomized controlled double-blind trial, patients aged over 18 years presenting with gastritis-related heartburn were eligible. Study patients received 40 mg esomeprazole or pantoprazole in 100 ml normal saline. Pain intensity was measured on a visual analog scale (VAS) at 30, 60, and 120 min. Patients were randomized and assigned to either of the two study arms via closed envelopes.

Results

Finally, 205 patients were randomized (esomeprazole: 104; pantoprazole 101). Mean age was 39.1 ± 13.78 years and 48.8% were male. Both esomeprazole (median VAS: 26 mm, interquartile range [IQR]: 17–38 mm) and pantoprazole (median: 24 mm, IQR: 14.5–36 mm) effectively reduced heartburn at 30 min, 60 min (median: 59.5 mm, IQR: 48–73.5 mm vs. 55 mm, IQR: 33–68.5 mm), and 120 min (median: 80 mm, IQR: 66.5–89.8 mm vs. 77 mm, IQR: 56–85 mm). While there was no statistically significant difference between the two drugs at 30 min (p = 0.312), there was a statistically significant difference in pain intensity between the esomeprazole and pantoprazole groups at 60 and 120 min (p = 0.014, p = 0.02, respectively).

Conclusion

Single-dose slow IV infusion of esomeprazole is faster and more effective in controlling heartburn than pantoprazole.
Literatur
1.
Zurück zum Zitat Mahadeva S, Goh KL (2006) Epidemiology of functional dyspepsia: a global perspective. World J Gastroenterol 12:2661–2666CrossRef Mahadeva S, Goh KL (2006) Epidemiology of functional dyspepsia: a global perspective. World J Gastroenterol 12:2661–2666CrossRef
2.
Zurück zum Zitat Musikatavorn K, Tansangngam P, Lumlertgul S et al (2012) A randomized controlled trial of adding intravenous pantoprazole to conventional treatment for the immediate relief of dyspeptic pain. Am J Emerg Med 30:1737–1742CrossRef Musikatavorn K, Tansangngam P, Lumlertgul S et al (2012) A randomized controlled trial of adding intravenous pantoprazole to conventional treatment for the immediate relief of dyspeptic pain. Am J Emerg Med 30:1737–1742CrossRef
3.
Zurück zum Zitat Jones R, Crouch L (1999) Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. Aliment Pharmacol Ther 13:413–419CrossRef Jones R, Crouch L (1999) Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. Aliment Pharmacol Ther 13:413–419CrossRef
4.
Zurück zum Zitat Fennerty MB, Johanson J, Hwang C et al (2005) Efficacy of esomeprazole 40 mg vs lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 21:455–463CrossRef Fennerty MB, Johanson J, Hwang C et al (2005) Efficacy of esomeprazole 40 mg vs lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 21:455–463CrossRef
5.
Zurück zum Zitat Labenz J, Armstrong D, Lauritsen K et al (2005) A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 21:739–746CrossRef Labenz J, Armstrong D, Lauritsen K et al (2005) A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 21:739–746CrossRef
6.
Zurück zum Zitat Kahrilas PJ, Falk GW, Johnson DA et al (2000) Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 14:1249–1258CrossRef Kahrilas PJ, Falk GW, Johnson DA et al (2000) Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 14:1249–1258CrossRef
7.
Zurück zum Zitat Lee TJ, Fennerty MB, Howden CW (2007) Systematic review: Is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? Aliment Pharmacol Ther 20(11-12):1241–1251CrossRef Lee TJ, Fennerty MB, Howden CW (2007) Systematic review: Is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? Aliment Pharmacol Ther 20(11-12):1241–1251CrossRef
8.
Zurück zum Zitat Lindblad AJ, Sadowski CA (2008) The safety of proton pump inhibitors. CPJ/RPC 141(suppl 1):S19–S21 Lindblad AJ, Sadowski CA (2008) The safety of proton pump inhibitors. CPJ/RPC 141(suppl 1):S19–S21
9.
Zurück zum Zitat Miner P Jr, Katz PO, Chen Y et al (2003) Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 98(12):2616–2620CrossRef Miner P Jr, Katz PO, Chen Y et al (2003) Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 98(12):2616–2620CrossRef
10.
Zurück zum Zitat Rohss K, Lind T, Wilder-Smith C (2004) Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg, in patients with gastroesophageal reflux symptoms. Eur J Clin Pharmacol 60(8):531–539CrossRef Rohss K, Lind T, Wilder-Smith C (2004) Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg, in patients with gastroesophageal reflux symptoms. Eur J Clin Pharmacol 60(8):531–539CrossRef
12.
Zurück zum Zitat Wilder-Smith C, Röhss K, Bondarov P et al (2005) Intravenous esomeprazole 40 mg is effective for the control of intragastric acid levels whether given as a 3-minute injection or a 30-minute infusion. Clin Drug Investig 25(8):517–525CrossRef Wilder-Smith C, Röhss K, Bondarov P et al (2005) Intravenous esomeprazole 40 mg is effective for the control of intragastric acid levels whether given as a 3-minute injection or a 30-minute infusion. Clin Drug Investig 25(8):517–525CrossRef
13.
Zurück zum Zitat Abelo A, Andersson TB, Antonsson M et al (2000) Stereoselective metabolism of omeprazole by human cyto chrome P450 enzymes. Drug Metab Dispos 28(8):966–972PubMed Abelo A, Andersson TB, Antonsson M et al (2000) Stereoselective metabolism of omeprazole by human cyto chrome P450 enzymes. Drug Metab Dispos 28(8):966–972PubMed
Metadaten
Titel
Intravenous esomeprazole versus pantoprazole for heartburn
A randomized controlled double-blind trial
verfasst von
O. Karakayali
S. Yilmaz, Prof.
A. Karakayali
Yavuz Yigit
Huseyin Cahit Halhalli
Tolga Uslu
Publikationsdatum
08.08.2019
Verlag
Springer Medizin
Erschienen in
Notfall + Rettungsmedizin / Ausgabe 4/2020
Print ISSN: 1434-6222
Elektronische ISSN: 1436-0578
DOI
https://doi.org/10.1007/s10049-019-0626-9

Weitere Artikel der Ausgabe 4/2020

Notfall + Rettungsmedizin 4/2020 Zur Ausgabe

ERC-Leitlinien

Ausbildung

Neu im Fachgebiet AINS

Nach größerer Op.: Wie lang in der PACU überwachen?

Ein etwa vier- bis sechsstündiges Monitoring im Aufwachraum (PACU) scheint in den meisten Fälle auszureichend zu sein, um anhand klinischer Kriterien zu entscheiden, ob es nach einer größeren Op. auf die Normalstation gehen kann.

Herzstillstand: Die „goldene Stunde“ der kardiopulmonalen Reanimation

Die Überlebenschancen von Menschen mit Herzstillstand hängen entscheidend davon ab, wie rasch Maßnahmen zur Reanimation in der „Golden Hour of ROSC“ getroffen werden, so Prof. Alexander Ghanem bei den DGK-Herztagen 2024.

Akutes Skrotum – im Notfall rasch handeln

Urogenitale Notfälle wie das akute Skrotum sind in der kinderärztlichen Praxis eine Herausforderung. Anamnese, Klinik und die Sonografie liefern wertvolle diagnostische Hinweise. Wann muss sofort operiert werden, wann reichen Bettruhe, Kühlung und Analgesie aus?

Lidocain bei Anlage eines intraossären Zugangs ist obsolet

Die notfallmedizinischen pädiatrischen Fachgesellschaften haben sich zur Gabe von Lidocain geäußert, die den Punktions- bzw. Injektionsschmerz beim Anlegen eines intraossären Zugangs verhindern soll. Sie raten dringend zum Verzicht.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.